Gemcitabine: A pharmacologic and clinical overview

被引:104
作者
Barton-Burke, M
机构
[1] Consulting Serv Boston, Boston, MA USA
[2] Univ Rhode Isl, Kingston, RI 02881 USA
关键词
cancer; chemotherapeutic agent; clinical benefit response; gemcitabine; nursing care;
D O I
10.1097/00002820-199904000-00011
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
There have been exciting new developments in anticancer therapy over the past few years. One such therapy uses gemcitabine (GemzarR), an antimetabolite approved in 1996 by the Food and Drug Administration (FDA) for first-line treatment of locally advanced (nonresectable stage II or stage III) or metastatic (stage N) adenocarcinoma of the pancreas. This novel nucleoside analog resembles the naturally occurring pyrimidine nucleoside deoxycytidine, but it has a unique mechanism of action. Clinical studies with gemcitabine have demonstrated anticancer activity in pancreatic cancer; non-small-cell lung cancer; breast, bladder, and ovarian cancers; and small-cell lung cancer. Clinical trials in patients with cancer of the pancreas used a novel study endpoint called clinical benefit response (CBR) to measure gemcitabine's effect on disease-related symptoms. The CBR is a composite assessment of performance status, pain, and weight gain. Studies show that gemcitabine has a relatively mild safety profile, with myelosuppression as the major dose-limiting toxicity. The aim of this review is to provide the oncology nurse with an overview of gemcitabine's pharmacology, innovative clinical trial end points, and clinical performance, as well as the nursing care required for the patient receiving this drug.
引用
收藏
页码:176 / 183
页数:8
相关论文
共 45 条
  • [31] PEREZMANGA G, 1996, ANN ONCOL, V7, P24
  • [32] Preclinical characteristics of gemcitabine
    Plunkett, W
    Huang, P
    Gandhi, V
    [J]. ANTI-CANCER DRUGS, 1995, 6 : 7 - 13
  • [33] WEEKLY GEMCITABINE IN ADVANCED BLADDER-CANCER - A PRELIMINARY-REPORT FROM A PHASE-I STUDY
    POLLERA, CF
    CERIBELLI, A
    CRECCO, M
    CALABRESI, F
    [J]. ANNALS OF ONCOLOGY, 1994, 5 (02) : 182 - 184
  • [34] RICHARDS F, 1994, P AN M AM SOC CLIN, V13, P344
  • [35] Rothenberg ML, 1996, ANN ONCOL, V7, P347
  • [36] SANDLER AB, 1995, P AN M AM SOC CLIN, V14, P357
  • [37] Activity of gemcitabine in patients with advanced ovarian cancer: Responses seen following platinum and paclitaxel
    Shapiro, JD
    Millward, MJ
    Rischin, D
    Michael, M
    Walcher, V
    Francis, PA
    Toner, GC
    [J]. GYNECOLOGIC ONCOLOGY, 1996, 63 (01) : 89 - 93
  • [38] Phase II trials of single-agent activity of gemcitabine in patients with advanced non-small cell lung cancer: An overview
    Shepherd, FA
    [J]. ANTI-CANCER DRUGS, 1995, 6 : 19 - 25
  • [39] Phase I dose-escalation trial of gemcitabine and cisplatin for advanced non-small-cell lung cancer: Usefulness of mathematic modeling to determine maximum-tolerable dose
    Shepherd, FA
    Burkes, R
    Cormier, Y
    Crump, M
    Feld, R
    Strack, T
    Schulz, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (05) : 1656 - 1662
  • [40] SNADLER A, 1996, ANN ONCOL S5, V7